Imipramine Pamoate in the Treatment of Childhood Enuresis

Martin, Gilbert I.

doi:10.1001/archpedi.1971.02110010078013

Cited by 46 publications

(5 citation statements)

References 33 publications

(2 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This result is also supported by several other studies where they found imipramine cured patients with primary enuresis during treatment period and after discontinuation of therapy it cause relapse in significant cases [19][20][21].…”

Section: Discussionsupporting

confidence: 85%

A Randomized Clinical Trial on Imipramine and Oxybutynin for the Treatment of Children With Primary Nocturnal Enuresis

Gupta¹,

Rasiduzzaman²,

Haque³

et al. 2020

Bang J Urology

View full text Add to dashboard Cite

Background: Nocturnal enuresis is a common childhood problem. There are several treatment options for the treatment of children with primary enuresis including behavioral modification, drug therapy like tricyclic antidepressant, vasopressin analog and anticholinergic drugs. Objective: To observe the efficacy of oxybutynin and imipramine for the treatment of children with primary nocturnal enuresis in terms of symptom relief and disease control. Materials and methods: A randomized clinical trial was conducted in urology outpatient department, Sir Salimullah Medical College Mitford Hospital, Dhaka from May 2015 to April 2016. Total 70 patients with primary nocturnal enuresis were selected according to selection criteria. After duly taking informed written consent, patients were randomly divided into 2 groups by lottery method. In this way 35 patients were selected as group- A and 35 patients were selected as group-B. Patients of group-A were treated with imipramine and Group-B were treated with oxybutynin. Results: Age range of the subjects was from 5-16 years. Among them 30% of the subjects in the imipramine group were between 7-9 years of age and 30% of the subjects in the oxybutynin group were between 5-7 years of age. The male-female ratio was 1.2:1.Thirty five percent of the subjects had positive family history while remaining 65% did not have such history. At the base line study, 80% of the subjects did not show satisfactory result following 2 weeks of behavioral modification while 20% showed improvement. Before starting drug therapy, 60% patients had 4-5 bed-wetting nights/week. Following treatment, frequency of bed wetting dropped sharply to <3 at the end of month 3 and begin to rise again after discontinuation of therapy. At the end of month 3, imipramine cured in 46.7% cases with adverse effects like insomnia, nausea, anxiety, palpitation, lethargy while oxybutynin cured 40% patients with more adverse effects like headache, palpitation, dry mouth, constipation, tiredness, nervousness and fever. Early relapse of nocturnal enuresis 3 months after withdrawal the drugs and it was higher in the imipramine treated group than oxybutynin treated group which was 47.8% and 45% respectively. Conclusion: Outcome of imipramine is better than oxybutynin and side effects are significantly higher in oxybutynin. I Bangladesh Journal of Urology, Vol. 21, No. 2, July 2018 p.76-82

show abstract

Section: Discussionsupporting

confidence: 85%

A Randomized Clinical Trial on Imipramine and Oxybutynin for the Treatment of Children With Primary Nocturnal Enuresis

Gupta¹,

Rasiduzzaman²,

Haque³

et al. 2020

Bang J Urology

View full text Add to dashboard Cite

show abstract

“…The old tricyclic antidepressant imipramine has in numerous studies proven to be superior to placebo in the treatment of unselected children with nocturnal enuresis [12][13][14][15]. For several decades, it was more or less the drug of choice and was widely prescribed all over the world.…”

Section: Introductionmentioning

confidence: 99%

Tolterodine and imipramine in refractory enuresis; a placebo-controlled crossover study

Nevéus

Tullus

2007

Pediatr Nephrol

View full text Add to dashboard Cite

The anticholinergic drug tolterodine has been suggested to be useful in therapy-resistant enuresis. Imipramine has a proven efficiency in unselected enuretic patients, but due to its side-effect profile it is only indicated, if at all, in therapy-resistant cases. We therefore compared these two drugs to placebo. Twenty-seven children with enuresis resistant to the alarm and to desmopressin in monotherapy were given placebo, tolterodine 1-2 mg, and imipramine 25-50 mg at bedtime for 5 weeks each in a randomised, double-blind, crossover fashion. The number of wet nights during the last 2 weeks of each treatment period was compared. One patient became spontaneously dry at the start of the study, and one dropped out due to side effects. Among the remaining 25 children, the number of wet nights during placebo, tolterodine and imipramine treatment were 11.0 +/- 3.9, 10.4 +/- 3.9 and 7.8 +/- 5.1, respectively (p < 0.001). Imipramine was significantly better than both placebo (p = 0.001) and tolterodine (p = 0.006). Nine children experienced side effects on imipramine and one on tolterodine (p = 0.001). This is the first study on anticholinergics or imipramine in children with therapy-resistant enuresis. Tolterodine, in monotherapy, had no proven effect. Imipramine was better than placebo, but side effects were common.

show abstract

“…This was probably a result of reports of their value in the treatment of this condition (Epstein and Guilfoyle, 1965;Kardash et al, 1968;Esperanca and Gerrard, 1969;Martin, 1971;Fraser, 1972;Kolvin et al, 1972). In our series however, parents seemed quite unaware of the potential dangers of these drugs.…”

Section: Discussionmentioning

confidence: 61%